

1 **Preexisting and new-onset diabetes in patients with COVID-19 pneumonia.**

2 Andrea Laurenzi, MD<sup>1</sup>, Amelia Caretto, MD<sup>1</sup>, Chiara Molinari, MD<sup>1</sup>, Elena Bazzigaluppi, B.Sc<sup>1</sup>;  
3 Cristina Brigatti, B.Sc<sup>1</sup>; Ilaria Marzinotto, PhD<sup>1</sup>; Alessia Mercalli, B.Sc<sup>1</sup>; Raffaella Melzi, B.Sc<sup>1</sup>;  
4 Rita Nano, B.Sc<sup>1</sup>; Cristina Tresoldi, B.Sc<sup>2</sup>; Giovanni Landoni, MD<sup>3,4</sup>; Fabio Ciceri, MD<sup>4,5</sup>; Vito  
5 Lampasona, B.Sc<sup>1</sup>; Marina Scavini, MD<sup>1</sup>; Lorenzo Piemonti, MD<sup>1,4</sup>.

6

7 <sup>1</sup> San Raffaele Diabetes Research Institute, IRCCS Ospedale San Raffaele, Via Olgettina 60, 20132  
8 Milan, Italy.

9 <sup>2</sup> Molecular Hematology Unit, IRCCS Ospedale San Raffaele, Via Olgettina 60, 20132 Milan, Italy.

10 <sup>3</sup> Department of Anesthesia and Intensive Care, IRCCS Ospedale San Raffaele, Via Olgettina 60,  
11 20132 Milan, Italy

12 <sup>4</sup> Università Vita-Salute San Raffaele, Milan, Italy.

13 <sup>5</sup> Hematology and Bone Marrow Transplantation Unit, IRCCS Ospedale San Raffaele, Via  
14 Olgettina 60, 20132 Milan, Italy.

15

16 **Short title:** SARS-CoV2 and diabetes

17 **Keywords:** COVID-19, diabetes, clinical outcome, humoral response, SARS-CoV-2

18 **Correspondence to:** Lorenzo Piemonti, Diabetes Research Institute, San Raffaele Scientific

19 Institute, Via Olgettina 60, 20132 Milan, Italy. Tel: 39 02 26432706, Fax: 39 02 26432871, E-mail:

20 piemonti.lorenzo@hsr.it

21

22 Word count: text: 3437 words, 2 tables and 2 figures

23

24 **Declaration of interests.** The authors have no conflict of interest to disclose in relation to the topic

25 of this manuscript. This work was funded by Program Project COVID-19 OSR-UniSR and

26 Ministero della Salute (COVID-2020-12371617).

27 **ABSTRACT**

28 **Objective.** The aim of the current study was to compare clinical characteristics, laboratory findings  
29 and major outcomes of patients hospitalized for COVID-19 pneumonia with new-onset or  
30 preexisting diabetes.

31 **Design.** A cohort of 176 adult patients with a diagnosis of pre-existing (n=112) or new-onset  
32 diabetes (n=55) and confirmed COVID-19 pneumonia was studied. Clinical outcomes and  
33 laboratory findings were analysed according to the presence of preexisting or new-onset diabetes.  
34 The time to viral clearance and the persistence of hyperglycemia were assessed during the follow-  
35 up after hospital discharge.

36 **Results.** Patients with new-onset diabetes had lower BMI, significantly less comorbidities and  
37 higher levels of inflammatory markers and indicators of multi-organ injury than those with  
38 preexisting diabetes. No differences between preexisting and new onset diabetes were evident for  
39 symptoms at admission, humoral response against SARS-CoV-2 or autoantibodies to glutamic acid  
40 decarboxylase or interferon alpha-4. New-onset diabetes was independently associated with the risk  
41 of adverse clinical outcome defined as ICU admission or death (HR 2.11, 95% CI 1.34-3.31;  
42 p=0.001), even after adjustment for age, sex and other selected variables associated with COVID-19  
43 severity. Furthermore, we documented a negative association (HR 0.661, 95% CI 0.43-1.02;  
44 p=0.063) between new-onset diabetes and the time to swab negativization. During follow-up we  
45 observed that in 30% of the patients with new-onset diabetes hyperglycemia reversed when the viral  
46 infection resolved.

47 **Conclusions.** The recognition of new-onset diabetes as a specific clinical entity associated with  
48 COVID-19 pneumonia is relevant for early and appropriate patient management and close  
49 monitoring for the progression of disease severity.

50 **INTRODUCTION**

51 Increasing evidence suggests the existence of a bidirectional link between COVID 19 and diabetes  
52 <sup>1</sup>. Preexisting diabetes is a risk factor for poor outcomes and death after SARS-CoV-2 infection <sup>2-4</sup>.  
53 On the other hand, new-onset diabetes/hyperglycemia <sup>5</sup> and acute metabolic decompensation of  
54 preexisting diabetes <sup>6</sup> are now emerging as complications of COVID-19 pneumonia, especially in  
55 patients requiring hospitalization. This suggests a potential diabetogenic effect of SARS-CoV-2  
56 infection, independent from the stress response to the acute illness <sup>7</sup>. Both reduced insulin secretion  
57 and increased insulin resistance have been proposed as possible mechanisms <sup>8</sup>. In fact, both  
58 endocrine and exocrine pancreatic tissues are susceptible to productive SARS-CoV-2 infection <sup>9,10</sup>,  
59 which may damage  $\beta$ -cell integrity, and decrease insulin secretion. Furthermore, the surge in  
60 cytokines production associated with the viral infection may be responsible for an increase in  
61 insulin resistance<sup>11</sup>. Regardless of the mechanism responsible for the metabolic dysregulation  
62 observed in patients with COVID-19 pneumonia, the clinical entity of new-onset  
63 diabetes/hyperglycemia still has not been adequately characterized and separated from the entity of  
64 preexisting diabetes <sup>5</sup>. Few studies have comparatively characterized the two types of diabetes as  
65 for the presence of comorbidities, pre-hospitalization treatments, symptoms at admission and  
66 laboratory variables associated with the severity of COVID-19 pneumonia. Many studies have  
67 recently reported that new-onset diabetes/hyperglycemia is associated with a poorer outcome  
68 compared to that of the normoglycemic individuals <sup>12-17</sup>. However, whether new-onset  
69 diabetes/hyperglycemia is associated with a poorer outcome of COVID-19 pneumonia compared to  
70 preexisting diabetes is still an open question, with conflicting findings <sup>13, 15, 18-20</sup>. Moreover, data on  
71 islet autoimmunity prevalence, anti SARS-CoV-2 antibody responses, and timing for viral clearance  
72 are still missing. Finally, it is unclear whether new-onset diabetes/hyperglycemia associated with  
73 COVID-19 pneumonia persists or reverts when the viral infection resolves. To address this gap in  
74 our knowledge, we studied a cohort of 176 adult patients with confirmed COVID-19 pneumonia,  
75 with a diagnosis of preexisting or new-onset diabetes.

76

## 77 **MATERIAL AND METHODS**

78 **Study population and data sources.** The study population consisted of 176 adult patients  
79 hospitalized for COVID-19 pneumonia with a diagnosis of diabetes, either preexisting or new-  
80 onset. These patients were selected from two previously described and partially overlapping cohorts  
81 <sup>12</sup>, assembled at the IRCCS San Raffaele Hospital (Milan, Italy) as part of an institutional clinical-  
82 biological cohort (COVID-BioB; ClinicalTrials.gov Identifier: NCT04318366) of patients with  
83 COVID-19 pneumonia. The first cohort (n=584) was previously analysed for the humoral response  
84 against SARS-Cov-2 (n = 509) <sup>21</sup>, while the second cohort (n=169) was studied for the development  
85 of thromboembolic complications. The study was approved by the local Institutional Review Board  
86 (protocol n 34/int/2020; NCT04318366) and all patients signed a written informed consent. A  
87 confirmed case was defined as presence of symptoms and radiological findings suggestive of  
88 COVID-19 pneumonia and/or a SARS-CoV-2-positive RT-PCR test from a nasal/throat (NT) swab.  
89 Demographic information, clinical features and laboratory tests were obtained within 72 hours from  
90 admission. Data were collected directly through patients' interviews or medical chart review. Data  
91 regarding patients' comorbidities were collected during hospitalization or after discharge from both  
92 structured baseline patient interviews and hospital paper or electronic medical records. All disease  
93 diagnoses present at the date of infection were included as comorbidities. Data were verified by data  
94 managers and clinicians for accuracy and crosschecked in blind. Data were recorded until hospital  
95 discharge or in-hospital death, whichever occurred first. We also recorded mortality and swab  
96 negativization beyond hospital discharge through our dedicate follow-up clinic: for patients non  
97 attending the follow-up clinic, we verified patient's vital status with either family members or  
98 family physician.

99 **Laboratory variables** Routine blood tests encompassed serum biochemistry [including renal and  
100 liver function, lactate dehydrogenase (LDH)], complete blood count with differential, markers of  
101 myocardial damage [troponin T and pro-brain natriuretic peptide (proBNP)], and inflammation

102 markers [C-reactive protein (CRP), ferritin, erythrocyte sedimentation rate (ESR), interleukin-6 (IL-  
103 6), procalcitonin]. An extended coagulation profile was obtained including D-dimer, PT, PTT,  
104 fibrinogen and antithrombin activity. Specific antibodies to different SARS-CoV-2 antigens,  
105 interferon alpha-4 and glutamic acid decarboxylase (GAD) were tested by a luciferase  
106 immunoprecipitation system (LIPS) assay, as previously described (11).

107 **Definition of diabetes.** Study participants were defined as having: a) preexisting diabetes if they  
108 had a documented diagnosis of diabetes before the hospital admission for COVID-19 pneumonia  
109 [fasting plasma glucose (FPG)  $\geq 7.0$  mmol/l or HbA1c  $\geq 6.5\%$  (48 mmol/mol), or they were  
110 prescribed diabetes medications]; b) new-onset diabetes if they had a mean fasting plasma glucose  
111 in the absence of infusions of dextrose  $\geq 7.0$  mmol/l during the hospitalization for COVID-19  
112 pneumonia in the presence of a negative history for diabetes and/or normal glycated hemoglobin  
113 level in the last year and in the absence of prescribed diabetes medications. We computed mean  
114 fasting glucose and glucose variability (standard deviation) from all fasting laboratory glucose  
115 values measured during hospitalization. The diagnosis of pancreatogenic and steroid-induced  
116 diabetes was attributed to patients whose diabetes was reasonably secondary to their exocrine  
117 pancreatic disease or steroid use. The diagnosis of type 1 diabetes was attributed to patients whose  
118 diabetes at onset was associated with evidence of islet autoimmunity. The diagnosis of type 2  
119 diabetes was attributed to all patients who did not fulfil the criteria for any of the above.

120 **Statistical analysis.** Categorical variables are reported as frequency or percent, continuous  
121 variables as median with inter-quartiles range (IQR) in parenthesis. Categorical variables were  
122 compared using Chi-square or Fischer's exact test, as appropriate; continuous variables using the  
123 Mann-Whitney test. Associations between baseline variables and diabetes status was assessed by  
124 logistic regression. Multiple regression models, each adjusted for age and sex and one additional  
125 baseline variable of interest were performed. The effect estimates were reported as Odd Ratios  
126 (ORs), outcome variable were pre-existing diabetes ore new onset diabetes as appropriate to obtain  
127 OR  $> 1$ .

128 Survival was estimated according to Kaplan–Meier. The time-to-event was calculated from the date  
129 of symptom onset to the date of the event, or of last follow-up visit, whichever occurred first. We  
130 used univariate and multivariate Cox proportional hazards models to study the association between  
131 patient characteristics with time to adverse outcome (a composite endpoint of admission to ICU or  
132 death, whichever occurred first). The effect estimates were reported as Hazard Ratios (HRs) with  
133 the corresponding 95% CI estimated according to the Wald approximation. Multivariate analyses  
134 were performed including variables significant at the level of  $<0.1$  in the univariate analysis.  
135 Variables were excluded from multivariate Cox regression if they showed substantial biological  
136 redundancy with other variables (e.g., aspartate aminotransferase vs alanine aminotransferase), had  
137 data obtained for fewer than 78% of patients, in order to prevent model overfitting. Two-tailed P  
138 values are reported, with P value  $<0.05$  indicating statistical significance. All confidence intervals  
139 are two-sided and not adjusted for multiple testing. Statistical analyses were performed with the  
140 SPSS 24 (SPSS Inc. /IBM) and the R software version 3.4.0 (R Core Team (2020)).

141

## 142 **RESULTS**

143 **Study participants.** The study population consisted of 176 adult patients ( $\geq 18$  years) with diabetes  
144 and confirmed COVID-19 pneumonia admitted between February 25<sup>th</sup> and May 2<sup>nd</sup> 2020 to the  
145 Emergency or Clinical departments of the IRCCS San Raffaele Hospital (Milan, Italy). Among the  
146 176 cases included in the study 11 (6.3%) were discharged without hospitalization, 137 (77.8%)  
147 were treated with non-invasive ventilation and 39 (22.2%) were admitted to the ICU over the  
148 hospitalization period. The median hospital stay was 17 (8-17) days. As of February 14, 2021 the  
149 median follow-up time after symptoms onset was 213 (95% CI: 199-227) days. Sixty-four patients  
150 died (36.4%). According to the composite endpoint of ICU admission or death, 82 patients (46.6%)  
151 had an adverse in-hospital outcome.

152 **New-onset diabetes was associated with specific basal characteristics.** Preexisting and new-  
153 onset diabetes accounted for 68.8% (n=121) and 31.25% (n=55) of our cohort, respectively. Among

154 the 121 subjects with pre-existing diabetes, 109 (90.1%) were diagnosed with type 2 diabetes, 4  
155 (3.3%) with type 1 diabetes and 8 (6.6%) with secondary diabetes (5 pancreatogenic, 3 steroid-  
156 induced). The characteristics of the study participants for patients with pre-existing or new-onset  
157 diabetes at the time of hospitalization are reported in Table 1. Sex- and age-adjusted logistic  
158 regression analysis was used to assess the associations between baseline variables and preexisting  
159 vs new-onset diabetes. Higher BMI at admission [after log<sub>10</sub> transformation OR 19.44 (2.204-  
160 171.43), p=0.008], cardiovascular comorbidities [OR 3.16 (1.32-8.01), p=0.017], hypertension [OR  
161 2.14 (1.04-4.4), p=0.038], active neoplastic disease [OR 3.69 (1.045-1.305), p=0.043] and chronic  
162 kidney disease [OR 2.23 (0.897-5.56), p=0.084] were all associated with preexisting diabetes, while  
163 comorbid neurodegenerative diseases were associated with new-onset diabetes [OR 3.23 (1.044-  
164 10.02), p=0.042]. The median time from symptoms onset to hospital admission was 6 (2-9.5) and 7  
165 (3-10) days for patients with preexisting and new-onset diabetes, respectively (p=0.484). Patients  
166 with preexisting and new-onset diabetes reported similar symptoms at the time of hospital  
167 admission for COVID-19 pneumonia (Table 1).

168 **New-onset diabetes was associated with a specific clinical laboratory profile at admission.**

169 Upon admission (Table 2), patients with new-onset diabetes exhibited significantly higher white  
170 blood cell count [9.7 (6.1-14.3) vs 7.1 (5.4-10.4)  $\times 10^9/L$ , p=0.004], neutrophil count [8.4 (4.85-  
171 12.9) vs 5.2 (3.9-8.1)  $\times 10^9/L$ , p=0.003], and tissue damage markers [LDH 8.04 (5.35-16.63) vs 5.92  
172 (4.42-8.17)  $\mu\text{kat/L}$ , p=0.001; AST 0.95 (0.65-1.39) vs 0.63 (0.42-1.14)  $\mu\text{kat/L}$ , p=0.001; ALT 0.78  
173 (0.47-1.24) vs 0.53 (0.3-0.93)  $\mu\text{kat/L}$ , p=0.012] compared to patients with preexisting diabetes.  
174 Furthermore, an increase in procalcitonin [0.95 (0.49-3.58) vs 0.61 (0.31-1.38) ng/ml, p=0.014] and  
175 hemoglobin [12.9 (11.5-14.6) vs 12.5 (10.75-13.5) g/L, p= 0.042] was evident, with a trend also for  
176 ferritin [1254 (585-2433) vs 823 (462-1499)  $\mu\text{g/L}$ , p= 0.063] and total bilirubin [11.62 (8.16-18.81)  
177 vs 9.23 (5.39-14.87)  $\mu\text{mol/L}$ , p=0.054]. All the other laboratory variables associated with COVID-  
178 19 pneumonia severity, including inflammation indices (CRP and IL-6), hemostatic variables (D-

179 dimer levels, platelet count, fibrinogen, partial thromboplastin time and prothrombin time),  
180 biomarkers of myocardial damage (troponin T and Pro-BNP), markers of liver and kidney function  
181 (albumin, phosphatase alkaline, creatinine) and glucose control were similar between preexisting  
182 and new-onset diabetes. Antibody responses to SARS-CoV-2 were available for a large subgroup of  
183 patients (Table 2). No differences between preexisting and new-onset diabetes were evident for  
184 IgG, IgM and IgA responses to the SARS-CoV-2 spike protein (RBD or S1+S2), IgG response to  
185 NP, autoimmune antibodies anti GAD and anti interferon alpha-4.

186 **New-onset diabetes was associated with a worse clinical outcome.** Sex-and age-adjusted Cox  
187 proportional hazards model (HR 2.11, CI 1.34-3.31; p=0.001) and Kaplan-Meier estimator log-rank  
188 test (p=0.005) indicated that new-onset diabetes was strongly associated with an increased risk of  
189 adverse clinical outcome, as defined by composite endpoint of admission to ICU or death,  
190 whichever occurred first. (Fig 1 and Table 2). Laboratory variables associated with adverse clinical  
191 outcome in univariate Cox proportional hazards model, included inflammation indices (CRP, IL-6,  
192 ferritin, procalcitonin, low lymphocytes count, high white blood cell and neutrophil count),  
193 hemostatic parameters (D-dimer levels, fibrinogen and partial thromboplastin time), biomarkers of  
194 myocardial damage (troponin T and Pro-BNP), markers of liver and kidney dysfunction (albumin,  
195 total bilirubin and creatinine), markers of tissue damage (lactate dehydrogenase and aspartate  
196 transaminase) and markers of glucose control (fasting plasma glucose and glucose variability). Of  
197 note, the presence of hypertension (HR 0.59, CI 0.36-0.94; p=0.028) and the treatment with  
198 Angiotensin II receptor blocker (HR 0.44, CI 0.22-0.85; p=0.014) was associated to a decreased risk  
199 for adverse clinical outcome. A multivariable analysis using two different models confirmed new-  
200 onset diabetes (HR 2.68, CI 1.47-4.89; p=0.001 and HR 1.72, CI 0.95-3.09; p=0.073 respectively)  
201 as an independent predictor of adverse clinical outcome (Figure 1B) for patients with COVID-19  
202 pneumonia. To evaluate the specific impact of clinical characteristics and laboratory tests, the  
203 univariate Cox proportional hazards model was also conducted separately for patients with  
204 preexisting and those with new-onset diabetes. Although many analysed factors were similarly

205 associated with COVID-19 adverse clinical outcome in either new-onset or preexisting diabetes,  
206 some qualitative or quantitative differences emerged (fig 1B).

207 **Post discharge follow-up: time to NT swab negativization and persistence of hyperglycemia.**

208 As the prolonged viral shedding is a risk factor for poor outcome of COVID-19 and may interfere  
209 with the immunological mechanism of virus elimination, in our study population we evaluated the  
210 time to NT swab negativization. Sex-and age-adjusted Cox proportional hazards model (HR 0.661,  
211 95% CI 0.43-1.02; p=0.063) and Kaplan-Meier estimator log-rank test (45 days, 95% CI 37-52 vs  
212 35 days, 95% CI 29-41; p=0.023) documented a negative association between new-onset diabetes  
213 and the time to NT swab negativization. The entity of new-onset diabetes also include stress-  
214 induced hyperglycemia that may resolve during follow up. For this reason, we evaluated fasting  
215 blood glucose during the post-discharge follow up (i.e., at the 1, 3, 6, and 9 month outpatient visits).  
216 Among 121 subjects with preexisting diabetes, 40 died and 20 had no glucose measurements during  
217 follow up (median 6 month). Of the remaining 61 patients with a prescribed treatment for diabetes,  
218 six had normal fasting glucose (NFG) [9.8%, 90 (84.5-91.75) mg/dl], 21 impaired fasting glucose  
219 (IFG) [34.4%, 112 (108-119) mg/dl] and 34 fasting glucose in the diabetes range (DFG) [55.7%,  
220 160.5 (133-189.5) mg/dl]. Among 55 patients with new-onset diabetes, 23 died and 12 had no  
221 glucose measurements during follow up (median 6 month). Of the remaining 20 patients, none had  
222 a prescribed diabetes treatment during follow up: six showed normalization of their fasting glucose  
223 [30%; 86 (84-90 mg/dl)], while 14 were confirmed as having either IFG [n=8, 40%, 104 (100.2-  
224 111)] or DFG [n=6, 30%; 136 (126-148) mg/dl].

225

226 **DISCUSSION**

227 New-onset diabetes<sup>5</sup> is emerging as a common feature among patients hospitalized for COVID-19  
228 pneumonia<sup>22</sup>. This clinical entity still needs to be adequately characterized since there are only few  
229 studies documenting how new-onset diabetes differs from preexisting diabetes in COVID-19  
230 patients. To address this issue, we studied a cohort of 176 adult patients with COVID-19 pneumonia

231 with a diagnosis of preexisting or new-onset diabetes. Our study generated several interesting  
232 findings. First, patients with new-onset diabetes had significantly less comorbidities related to the  
233 metabolic syndrome than those with preexisting diabetes. The main reason for this difference  
234 probably lies in the lower prevalence of obesity and a shorter duration of hyperglycemia. Consistent  
235 with this, prior to admission only a low proportion of patients was prescribed antihypertensive  
236 drugs, lipid-lowering agents or antiplatelet therapy. However, it cannot be excluded that the lower  
237 prevalence is an effect related to an underdiagnosis driven by the absence of diabetes diagnosis.  
238 Similarly, the higher prevalence of neurodegenerative disease in subjects with “new onset diabetes”  
239 could be related with lower utilization of health care and therefore lower rates of diagnosis of  
240 diabetes pre admission in patients with a cognitive impairment. Second, patients with new-onset  
241 diabetes showed increased levels of inflammatory markers and indicators of multi-organ injury  
242 compared to patients with preexisting diabetes. Third, the prevalence of autoimmune biomarkers as  
243 anti GAD (a marker of islet autoimmunity) or interferon alpha-4 antibody (an autoimmune marker  
244 recently associated with COVID-19 severity)<sup>23</sup> was generally very low and did not differ between  
245 new-onset and preexisting diabetes. Fourth, new-onset diabetes was associated with a poorer  
246 clinical outcome and a delayed time to viral clearance compared to preexisting diabetes, despite the  
247 presence of a superimposable humoral responses to SARS-CoV-2 and similar glucose levels. Fifth,  
248 new-onset diabetes associated with severe COVID-19 pneumonia reversed in 30% of the patients  
249 when the viral infection resolved.

250 Whether new-onset diabetes should be considered a specific clinical entity is a matter of discussion.  
251 In terms of pathophysiology, new-onset diabetes may include (a) “stress-induced” hyperglycemia;  
252 (b) previously unrecognized (pre)diabetes (either type 2 or, less likely, type 1 diabetes); (c) a form  
253 of diabetes due to the direct effect of the SARS-CoV-2 virus on the pancreas; or (d) a form of  
254 diabetes secondary to the treatment of COVID-19 (e.g., with glucocorticoids or other medications  
255 possibly inducing secondary diabetes)<sup>24-31</sup>. To adequately addressing this question would require  
256 the availability of pancreatic tissue or advanced studies on insulin secretion and resistance, which

257 would be unrealistic to perform during the acute phase of COVID-19 pneumonia. Moreover, it is  
258 very likely that more than one cause may contribute to the hyperglycemia of new-onset diabetes. In  
259 our study, the absence of markers of islet autoimmunity and the lower prevalence of comorbidities  
260 related to metabolic syndrome do suggest specific pathophysiological mechanisms responsible for  
261 new-onset diabetes. More specifically, the extremely low prevalence of GAD autoantibodies  
262 excludes a previously unrecognized autoimmune (pre)diabetes (ie LADA) as possible cause of new  
263 onset diabetes. The use of glucocorticoids in the first wave of the pandemic was very limited and,  
264 therefore, unlikely to have played a role in the pathogenesis of new-onset diabetes. Moreover, as  
265 new-onset diabetes reverted in some patients when the infection resolved, it is reasonable to  
266 hypothesize that reversible transient factors, such as inflammation-induced insulin resistance, may  
267 play a role in causing hyperglycemia in those patients <sup>28</sup>.

268 Regardless of the pathophysiological mechanism, our study documented that new-onset diabetes  
269 was associated with an adverse clinical outcome of SARS-CoV-2 infection and that this association  
270 was independent from the major risk factors for COVID-19 disease severity. As good glycemic  
271 control was indeed shown to reduce disease severity and mortality in COVID-19 patients with  
272 hyperglycemia <sup>32</sup>, early recognition and treatment of hyperglycemia may greatly benefit these  
273 patients. Therefore, our findings do strongly support the need to screen all patients with COVID-19  
274 pneumonia for hyperglycemia (i.e., blood glucose and/or HbA1c) at the time of admission, despite a  
275 mute personal or family history of diabetes.

276 Since blood glucose levels in our study were not different in patients with either new-onset or  
277 preexisting diabetes, factors other than hyperglycemia should be considered to explain the  
278 differences in clinical outcome. A role could be played by a different drug treatment prior to  
279 admission, Of note, in our study sex-and age-adjusted Cox proportional hazards model indicated  
280 that angiotensin-converting enzyme inhibitors (ACEi) and/or angiotensin receptor blockers (ARB)  
281 treatment was significantly associated with a better clinical outcome in preexisting diabetes, but not  
282 in new-onset diabetes. Most studies, including several meta-analyses, found no substantial

283 differences in the risk for severe COVID-19 pneumonia associated with the prescription of common  
284 classes of antihypertensive medications<sup>33</sup>. On the other hand, evidence of the beneficial effects of  
285 chronic ACEi/ARB use, especially in hypertensive cohort of patients with COVID-19 pneumonia,  
286 was reported<sup>34-37</sup>. As the prevalence of hypertension is higher among patients with preexisting  
287 diabetes, ACEi/ARB use may mediate a selective beneficial effect. Similarly, in our study around  
288 60% of patients with preexisting diabetes was taking metformin and the treatment was associated  
289 with a better clinical outcome. Concordantly, previous observational studies suggested that in  
290 patients taking metformin the risk for COVID-19 mortality is reduced<sup>38, 39</sup>. Of note is the evidence  
291 of a delayed viral clearance after SARS-CoV-2 infection among patients with new-onset diabetes.  
292 Of great interest is also the finding of a slow viral clearance in COVID-19 pneumonia patients with  
293 new onset diabetes. Discordant data exist about differences in viral clearance or shedding in people  
294 with diabetes<sup>40</sup>. As increased glucose levels and glycolysis promoted Sars-CoV-2 replication in  
295 monocytes via ROS/HIF $\alpha$  pathway activation leading to secondary T-cell dysfunction<sup>41</sup>, this could  
296 explain the delayed viral clearance associated with the acute hyperglycaemia in patients with new-  
297 onset diabetes.

298 Our study has some limitations. First, the analysis was performed on a subcohort of 176 patients  
299 selected for having hyperglycemia (either new-onset or preexisting diabetes) out of 584 subjects of  
300 our original cohort (12). All patients with diabetes were included, and as for age, sex, new-onset  
301 diabetes prevalence, and the clinical outcome of our cohort appears superimposable to those  
302 reported by many authors. Despite this, we cannot exclude a selection bias. Second, our cohort is  
303 limited to hospitalized patients with COVID-19 pneumonia. Third, we only assessed fasting blood  
304 glucose and we acknowledge that more specific indicators of beta cell function, such as serum  
305 insulin and or C peptide levels, should have been measured. Fourth, the lack of HbA1c  
306 measurements in our cohort is a limitation. The evidence of normal HbA1c at the time of admission  
307 would indicate no history of recent hyperglycemia and confirm the diagnosis of new-onset diabetes.  
308 HbA1c levels were available for some patients with preexisting diabetes (51 (41-58) mmol/mol;

309 6.8%), but in very few patients with new-onset diabetes (38 (36-40) mmol/mol; 5.6%), and for this  
310 reason were not included in the analysis.

311 In conclusion, new-onset diabetes/hyperglycemia is emerging as a complication of COVID-19  
312 pneumonia and this clinical entity still needs to be adequately characterized in comparison with  
313 preexisting diabetes. It is clear from our study that patients with new-onset diabetes had increased  
314 levels of inflammatory markers and indicators of organ injuries associated with a poorer clinical  
315 outcome compared to preexisting diabetes. This strongly support the need to screen all COVID-19  
316 patients for hyperglycemia at the time of admission, despite a mute personal or family history of  
317 diabetes, and to treat them in order to reach and maintain a good glycemc control during the  
318 hospitalization for COVID-19 pneumonia.

319 DATA AVAILABILITY. Some or all datasets generated during and/or analyzed during the current  
320 study are not publicly available but are available from the corresponding author on reasonable  
321 request.

322

### 323 ACKNOWLEDGMENTS

324 This work was funded by Program Project COVID-19 OSR-UniSR and Ministero della Salute  
325 (COVID-2020-12371617).

326 *Declaration of interests.* The authors have no conflict of interest to disclose in relation to the topic  
327 of this manuscript. The authors declare that there are no relationships or activities that might bias, or  
328 be perceived to bias, their work.

329 *Individual contributions.* LP, VL and MS contributed to the conception of the study, wrote the  
330 manuscript, researched data and contributed to the discussion. EBa, CB and IM contributed to the  
331 acquisition and analysis of antibody data and revised the manuscript. AM, RM, CT, RT, FC and GL  
332 contributed to the acquisition of samples, managed the biobanking activities, critically revised the  
333 manuscript, recruited patients and managed sample biobanking. AL, AC and CM, contributed to  
334 the acquisition, analysis and interpretation of clinical data, contributed to the design of the study  
335 and critically reviewed/edited the manuscript. Professor Lorenzo Piemonti is the guarantor of this  
336 work and, as such, had full access to all the data presented in the study and takes responsibility for  
337 the integrity of data and the accuracy of data analysis. The final manuscript has been read and  
338 approved by all named authors.

339 **REFERENCE**

- 340 1. Muniangi-Muhitu H, Akalestou E, Salem V, Misra S, Oliver NS & Rutter GA. Covid-19  
341 and Diabetes: A Complex Bidirectional Relationship. *Front Endocrinol (Lausanne)* 2020 **11**  
342 582936.
- 343 2. McGurnaghan SJ, Weir A, Bishop J, Kennedy S, Blackburn LAK, McAllister DA,  
344 Hutchinson S, Caparrotta TM, Mellor J, Jeyam A, O'Reilly JE, Wild SH, Hatam S, Hohn A,  
345 Colombo M, Robertson C, Lone N, Murray J, Butterly E, Petrie J, Kennon B, McCrimmon  
346 R, Lindsay R, Pearson E, Sattar N, McKnight J, Philip S, Collier A, McMenemy J, Smith-  
347 Palmer A, Goldberg D, McKeigue PM & Colhoun HM. Risks of and risk factors for  
348 COVID-19 disease in people with diabetes: a cohort study of the total population of  
349 Scotland. *Lancet Diabetes Endocrinol* 2021 **9** 82-93.
- 350 3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu  
351 T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang  
352 G, Jiang R, Gao Z, Jin Q, Wang J & Cao B. Clinical features of patients infected with 2019  
353 novel coronavirus in Wuhan, China. *Lancet* 2020 **395** 497-506.
- 354 4. Mantovani A, Byrne CD, Zheng MH & Targher G. Diabetes as a risk factor for greater  
355 COVID-19 severity and in-hospital death: A meta-analysis of observational studies. *Nutr*  
356 *Metab Cardiovasc Dis* 2020.
- 357 5. Rubino F, Amiel SA, Zimmet P, Alberti G, Bornstein S, Eckel RH, Mingrone G, Boehm B,  
358 Cooper ME, Chai Z, Del Prato S, Ji L, Hopkins D, Herman WH, Khunti K, Mbanya JC &  
359 Renard E. New-Onset Diabetes in Covid-19. *N Engl J Med* 2020 **383** 789-790.
- 360 6. Li J, Wang X, Chen J, Zuo X, Zhang H & Deng A. COVID-19 infection may cause ketosis  
361 and ketoacidosis. *Diabetes, Obesity and Metabolism* 2020 **22** 1935-1941.
- 362 7. Hayden MR. An Immediate and Long-Term Complication of COVID-19 May Be Type 2  
363 Diabetes Mellitus: The Central Role of beta-Cell Dysfunction, Apoptosis and Exploration of  
364 Possible Mechanisms. *Cells* 2020 **9**.

- 365 8. Ceriello A. Hyperglycemia and COVID-19: What was known and what is really new?  
366 *Diabetes Res Clin Pract* 2020 **167** 108383.
- 367 9. Müller JA, Groß R, Conzelmann C, Krüger J, Merle U, Steinhart J, Weil T, Koepke L,  
368 Bozzo CP, Read C, Fois G, Eiseler T, Gehrman J, van Vuuren J, Wessbecher IM, Frick M,  
369 Costa IG, Breunig M, Grüner B, Peters L, Schuster M, Liebau S, Seufferlein T, Stenger S,  
370 Stenzinger A, MacDonald PE, Kirchhoff F, Sparrer KMJ, Walther P, Lickert H, Barth TFE,  
371 Wagner M, Münch J, Heller S & Kleger A. SARS-CoV-2 infects and replicates in cells of  
372 the human endocrine and exocrine pancreas. *Nature Metabolism* 2021.
- 373 10. Coate KC, Cha J, Shrestha S, Wang W, Goncalves LM, Almaca J, Kapp ME, Fasolino M,  
374 Morgan A, Dai C, Saunders DC, Bottino R, Aramandla R, Jenkins R, Stein R, Kaestner KH,  
375 Vahedi G, Brissova M & Powers AC. SARS-CoV-2 Cell Entry Factors ACE2 and  
376 TMPRSS2 Are Expressed in the Microvasculature and Ducts of Human Pancreas but Are  
377 Not Enriched in beta Cells. *Cell Metab* 2020 **32** 1028-1040 e1024.
- 378 11. Wu L, Girgis CM & Cheung NW. COVID-19 and diabetes: Insulin requirements parallel  
379 illness severity in critically unwell patients. *Clin Endocrinol (Oxf)* 2020 **93** 390-393.
- 380 12. Lampasona V, Secchi M, Scavini M, Bazzigaluppi E, Brigatti C, Marzinotto I, Davalli A,  
381 Caretto A, Laurenzi A, Martinenghi S, Molinari C, Vitali G, Di Filippo L, Mercalli A, Melzi  
382 R, Tresoldi C, Rovere-Querini P, Landoni G, Ciceri F, Bosi E & Piemonti L. Antibody  
383 response to multiple antigens of SARS-CoV-2 in patients with diabetes: an observational  
384 cohort study. *Diabetologia* 2020 **63** 2548-2558.
- 385 13. Li H, Tian S, Chen T, Cui Z, Shi N, Zhong X, Qiu K, Zhang J, Zeng T, Chen L & Zheng J.  
386 Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes  
387 in hospitalized patients with COVID-19. *Diabetes, Obesity and Metabolism* 2020 **22** 1897-  
388 1906.
- 389 14. Wang S, Ma P, Zhang S, Song S, Wang Z, Ma Y, Xu J, Wu F, Duan L, Yin Z, Luo H,  
390 Xiong N, Xu M, Zeng T & Jin Y. Fasting blood glucose at admission is an independent

- 391 predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of  
392 diabetes: a multi-centre retrospective study. *Diabetologia* 2020.
- 393 15. Fadini GP, Morieri ML, Boscari F, Fioretto P, Maran A, Busetto L, Bonora BM, Selmin E,  
394 Arcidiacono G, Pinelli S, Farnia F, Falaguasta D, Russo L, Voltan G, Mazzocut S,  
395 Costantini G, Ghirardini F, Tresso S, Cattelan AM, Vianello A, Avogaro A & Vettor R.  
396 Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by  
397 aggravating respiratory deterioration. *Diabetes Res Clin Pract* 2020 **168** 108374.
- 398 16. Bode B, Garrett V, Messler J, McFarland R, Crowe J, Booth R & Klonoff DC. Glycemic  
399 Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United  
400 States. *J Diabetes Sci Technol* 2020 **14** 813-821.
- 401 17. Singh AK & Singh R. Hyperglycemia without diabetes and new-onset diabetes are both  
402 associated with poorer outcomes in COVID-19. *Diabetes Research and Clinical Practice*  
403 2020 **167** 108382.
- 404 18. Cariou B, Pichelin M, Goronflot T, Gonfroy C, Marre M, Raffaitin-Cardin C, Thivolet C,  
405 Wargny M, Hadjadj S & Gourdy P. Phenotypic characteristics and prognosis of newly  
406 diagnosed diabetes in hospitalized patients with COVID-19: results from the CORONADO  
407 study. *Diabetes Res Clin Pract* 2021 108695.
- 408 19. Zhang Y, Li H, Zhang J, Cao Y, Zhao X, Yu N, Gao Y, Ma J, Zhang H, Zhang J, Guo X &  
409 Liu X. The clinical characteristics and outcomes of patients with diabetes and secondary  
410 hyperglycaemia with coronavirus disease 2019: A single-centre, retrospective, observational  
411 study in Wuhan. *Diabetes, Obesity and Metabolism* 2020 **22** 1443-1454.
- 412 20. Sachdeva S, Desai R, Gupta U, Prakash A, Jain A & Aggarwal A. Admission  
413 Hyperglycemia in Non-diabetics Predicts Mortality and Disease Severity in COVID-19: a  
414 Pooled Analysis and Meta-summary of Literature. *SN Compr Clin Med* 2020 1-6.
- 415 21. Secchi M, Bazzigaluppi E, Brigatti C, Marzinotto I, Tresoldi C, Rovere-Querini P, Poli A,  
416 Castagna A, Scarlatti G, Zangrillo A, Ciceri F, Piemonti L & Lampasona V. COVID-19

- 417 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor  
418 binding domain. *J Clin Invest* 2020 **130** 6366-6378.
- 419 22. Sathish T, Kapoor N, Cao Y, Tapp RJ & Zimmet P. Proportion of newly diagnosed diabetes  
420 in COVID-19 patients: A systematic review and meta-analysis. *Diabetes, Obesity and*  
421 *Metabolism* 2021 **23** 870-874.
- 422 23. Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, Dorgham K,  
423 Philippot Q, Rosain J, Beziat V, Manry J, Shaw E, Haljasmagi L, Peterson P, Lorenzo L,  
424 Bizien L, Trouillet-Assant S, Dobbs K, de Jesus AA, Belot A, Kallaste A, Catherinot E,  
425 Tandjaoui-Lambiotte Y, Le Pen J, Kerner G, Bigio B, Seeleuthner Y, Yang R, Bolze A,  
426 Spaan AN, Delmonte OM, Abers MS, Aiuti A, Casari G, Lampasona V, Piemonti L, Ciceri  
427 F, Bilguvar K, Lifton RP, Vasse M, Smadja DM, Migaud M, Hadjadj J, Terrier B, Duffy D,  
428 Quintana-Murci L, van de Beek D, Roussel L, Vinh DC, Tangye SG, Haerynck F, Dalmau  
429 D, Martinez-Picado J, Brodin P, Nussenzweig MC, Boisson-Dupuis S, Rodriguez-Gallego  
430 C, Vogt G, Mogensen TH, Oler AJ, Gu J, Burbelo PD, Cohen JI, Biondi A, Bettini LR,  
431 D'Angio M, Bonfanti P, Rossignol P, Mayaux J, Rieux-Laucat F, Husebye ES, Fusco F,  
432 Ursini MV, Imberti L, Sottini A, Paghera S, Quiros-Roldan E, Rossi C, Castagnoli R,  
433 Montagna D, Licari A, Marseglia GL, Duval X, Ghosn J, Tsang JS, Goldbach-Mansky R,  
434 Kisand K, Lionakis MS, Puel A, Zhang SY, Holland SM, Gorochoy G, Jouanguy E, Rice  
435 CM, Cobat A, Notarangelo LD, Abel L, Su HC & Casanova JL. Autoantibodies against type  
436 I IFNs in patients with life-threatening COVID-19. *Science* 2020 **370**.
- 437 24. Boddu SK, Aurangabadkar G & Kuchay MS. New onset diabetes, type 1 diabetes and  
438 COVID-19. *Diabetes Metab Syndr* 2020 **14** 2211-2217.
- 439 25. Papachristou S, Stamatou I, Stoian AP & Papanas N. New-Onset Diabetes in COVID-19:  
440 Time to Frame Its Fearful Symmetry. *Diabetes Therapy* 2021 **12** 461-464.

- 441 26. Unsworth R, Wallace S, Oliver NS, Yeung S, Kshirsagar A, Naidu H, Kwong RMW,  
442 Kumar P & Logan KM. New-Onset Type 1 Diabetes in Children During COVID-19:  
443 Multicenter Regional Findings in the U.K. *Diabetes Care* 2020 **43** e170-e171.
- 444 27. Nassar M, Nso N, Baraka B, Alfshawy M, Mohamed M, Nyabera A & Sachmechi I. The  
445 association between COVID-19 and type 1 diabetes mellitus: A systematic review. *Diabetes*  
446 *Metab Syndr* 2021 **15** 447-454.
- 447 28. Sathish T, Tapp RJ, Cooper ME & Zimmet P. Potential metabolic and inflammatory  
448 pathways between COVID-19 and new-onset diabetes. *Diabetes Metab* 2020 101204.
- 449 29. Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A & Del Prato S. COVID-  
450 19 in people with diabetes: understanding the reasons for worse outcomes. *Lancet Diabetes*  
451 *Endocrinol* 2020.
- 452 30. Smith SM, Boppana A, Traupman JA, Unson E, Maddock DA, Chao K, Dobesh DP,  
453 Brufsky A & Connor RI. Impaired glucose metabolism in patients with diabetes,  
454 prediabetes, and obesity is associated with severe COVID-19. *J Med Virol* 2020.
- 455 31. Wang J & Meng W. COVID-19 and diabetes: the contributions of hyperglycemia. *J Mol*  
456 *Cell Biol* 2020.
- 457 32. Sardu C, D'Onofrio N, Balestrieri ML, Barbieri M, Rizzo MR, Messina V, Maggi P,  
458 Coppola N, Paolisso G & Marfella R. Outcomes in Patients With Hyperglycemia Affected  
459 by COVID-19: Can We Do More on Glycemic Control? *Diabetes Care* 2020 **43** 1408-1415.
- 460 33. Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, Hausvater A,  
461 Newman JD, Berger JS, Bangalore S, Katz SD, Fishman GI, Kunichoff D, Chen Y,  
462 Ogedegbe G & Hochman JS. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of  
463 Covid-19. *N Engl J Med* 2020 **382** 2441-2448.
- 464 34. Baral R, White M & Vassiliou VS. Effect of Renin-Angiotensin-Aldosterone System  
465 Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872  
466 Patients. *Curr Atheroscler Rep* 2020 **22** 61.

- 467 35. Guo X, Zhu Y & Hong Y. Decreased Mortality of COVID-19 With Renin-Angiotensin-  
468 Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis.  
469 *Hypertension* 2020 **76** e13-e14.
- 470 36. Zhang X, Yu J, Pan LY & Jiang HY. ACEI/ARB use and risk of infection or severity or  
471 mortality of COVID-19: A systematic review and meta-analysis. *Pharmacol Res* 2020 **158**  
472 104927.
- 473 37. Barochiner J & Martinez R. Use of inhibitors of the renin-angiotensin system in  
474 hypertensive patients and COVID-19 severity: A systematic review and meta-analysis. *J*  
475 *Clin Pharm Ther* 2020 **45** 1244-1252.
- 476 38. Crouse AB, Grimes T, Li P, Might M, Ovalle F & Shalev A. Metformin Use Is Associated  
477 With Reduced Mortality in a Diverse Population With COVID-19 and Diabetes. *Frontiers*  
478 *in Endocrinology* 2021 **11**.
- 479 39. Han T, Ma S, Sun C, Zhang H, Qu G, Chen Y, Cheng C, Chen EL, Ahmed MA, Kim KY,  
480 Manem R, Chen M, Guo Z, Yang H, Yan Y & Zhou Q. The Association Between  
481 Hypoglycemic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A  
482 Systematic Review and Meta-Analysis. *medRxiv* 2021 2021.2001.2026.21250506.
- 483 40. Drucker DJ. Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the  
484 beginning. *Cell Metab* 2021 **33** 479-498.
- 485 41. Codo AC, Davanzo GG, de Brito Monteiro L, de Souza GF, Muraro SP, Virgilio-da-Silva  
486 JV, Prodonoff JS, Carregari VC, de Biagi Junior CAO & Crunfli F. Elevated glucose levels  
487 favor SARS-CoV-2 infection and monocyte response through a HIF-1 $\alpha$ /glycolysis-  
488 dependent axis. *Cell Metabolism* 2020 **32** 437-446. e435.
- 489
- 490

491 **FIGURE LEGENDS**

492 **Figure 1 a-b. Adverse clinical outcome in patients with COVID-19 pneumonia with either**  
493 **preexisting or new-onset diabetes.** Kaplan-Meier estimates of survival without adverse clinical  
494 outcome for 176 patients with COVID-19 pneumonia (panel a). Survival without adverse clinical  
495 outcome (defined by composite endpoint of admission to ICU or death, whichever occurred first)  
496 was estimated for patients with new-onset (n=55) or preexisting diabetes (n=121). The log-rank test  
497 was used to test differences between the two groups. Crosses indicate censored patients (censoring  
498 for death or end of follow-up). The forest plots (panel b) show the hazard ratios for survival without  
499 adverse clinical outcome according to presence of new-onset or preexisting diabetes. Left panel:  
500 univariate Cox regression analysis adjusted for sex and age. Right panel: multivariate Cox  
501 regression analysis adjusted for sex and age, including variables significant at the level of <0.1 in  
502 the univariate analysis. Variables were excluded from multivariate Cox regression if they showed  
503 substantial biological redundancy with other variables (e.g. aspartate aminotransferase vs alanine  
504 aminotransferase) or had data obtained for fewer than 78% of patients. Dots represent the HR, lines  
505 represent 95% confidence interval (CI), and solid dots indicate  $P < 0.05$ .

506

507 **Figure 2 a-b. Post discharge follow-up: time to NT swab negativization and persistence of**  
508 **hyperglycemia.** Kaplan-Meier estimates of the time to NT swab negativization for 176 patients  
509 with COVID-19 pneumonia (panel a). NT Swab negativization was estimated in patients with new-  
510 onset (n=55) or preexisting diabetes (n=121). The log-rank test was used to test differences between  
511 groups. Crosses indicate censored patients (censoring for death or end of follow-up). Fasting blood  
512 glucose during the post discharge follow up (panel b). Valid glucose measurements during follow  
513 up (median 6 month) was available for 61 out of 121 and 20 out of 55 patients with preexisting or  
514 new-onset diabetes, respectively. NFG: Normal Fasting Glucose, <5.6 mmol/L; IFG: Impaired  
515 Fasting Glucose 5.6-6.9 mmol/L; DFG: Diabetes Fasting Glucose  $\geq 7$  mmol/L.

516  
517  
518

**Tables**

**Table 1. Baseline characteristics of study cohort, according to either preexisting or new-onset diabetes**

	Preexisting diabetes	New-onset diabetes	p	Missing
N	121	55		
Age, years	71 (62-77.5)	69 (54-78)	0.324	0
Sex, male [N (%)]	84 (71.2)	37 (63.8)	0.387	0
BMI	29.16 (26.12-33.8)	26.52 (23.87-30.12)	0.014	
- <25 [N (%)]	23 (20.5)	14 (31.8)		20
- 25-30 [N (%)]	36 (32.1)	19 (43.2)	0.036	
- >30 [N (%)]	53 (47.3)	11 (25)		
Ethnicity [N (%)]				
- Caucasian	106 (87.6)	48 (87.3)		0
- Hispanic	7 (5.8)	3 (5.5)	0.998	
- Asian	4 (3.3)	2 (3.6)		
- African	4 (3.3)	2 (3.6)		
Comorbidities [N (%)]				
- Hypertension	91 (75.2)	32 (58.2)	0.033	0
- Coronary Artery Diseases	35 (28.9)	6 (10.9)	0.012	
- COPD	16 (13.2)	5 (9.1)	0.617	
- Chronic Kidney Disease	32 (26.4)	7 (12.7)	0.05	
- Cancer	23 (19)	3 (5.5)	0.021	
- Neurodegenerative disease	7 (5.8)	8 (14.5)	0.078	
Preadmission treatment [N (%)]				
- Metformin	71 (58.7)	0		0
- Sulfonylureas	12 (9.9)	0		
- Repaglinide	3 (2.5)	0		
- Acarbose	3 (2.5)	0		
- Thiazolidinediones	1 (0.8)	0		
- DPP-4 inhibitors	14 (11.6)	0		
- GLP-1 agonist	3 (2.5)	0		
- SGLT2 inhibitors	4 (3.3)	0		
- Insulin	41 (33.9)	0		
- ASA	47 (38.8)	7 (12.7)	<0.001	
- Statin	44 (36.4)	6 (10.9)	0.001	
- ACE inhibitors	28 (23.1)	11 (20)	0.699	
- Angiotensin II R blockers	28 (23.1)	6 (10.9)	0.065	
- ACEI and/or ARB	54 (44.6)	17 (30.9)	0.099	
- Calcium channel blockers	35 (28.9)	9 (16.4)	0.091	
- Beta blockers	43 (35.5)	13 (23.6)	0.162	
<b>Admission to the hospital</b>				
Median time from symptoms to admission, days	6 (2-9.5)	7 (3-10)	0.484	
Symptoms at onset [N (%)]				
- fever	93 (78.2)	46 (85.2)	0.31	0
- dyspnea	79 (66.4)	37 (68.5)	0.86	
- cough	46 (38.7)	21 (38.9)	0.99	
- fatigue/malaise	35 (29.4)	10 (18.5)	0.14	
- hypo/dysgeusia	19 (17.3)	8 (14.8)	0.82	
- hypo/anosmia	17 (14.3)	8 (14.8)	0.99	
- myalgia/arthralgia	19 (16)	7 (13)	0.82	
- headache	12 (10.1)	1 (1.9)	0.066	
- chest pain	12 (10.1)	2 (3.7)	0.23	
- diarrhea	16 (13.4)	6 (11.1)	0.81	
- sore throat	5 (4.2)	6 (11.1)	0.10	
- vomiting/nausea	9 (7.6)	6 (11.1)	0.56	
- conjunctivitis	8 (6.7)	5 (9.3)	0.55	
- abdominal pain	5 (4.2)	2 (3.7)	0.99	
- skin rash	2 (1.9)	0	0.99	

519  
520


521  
522

**Table 2. Clinical laboratory profile at hospital admission and clinical outcome**

	Pre-existing diabetes	New-onset diabetes	p*	Missing
N	121	55		
<b>Clinical outcomes</b>				
Median follow up, days (95% CI)	222 (202-242)	190 (98-282)	0.065	
After admission [N (%)]				
- Discharged	79 (65.3)	32 (58.2)		
o Not hospitalized	7 (8.9)	4 (12.5)		0
o Hospitalized ≤7days	14 (17.7)	1 (3.1)	0.008	
o Hospitalized >7days	51 (64.6)	17 (53.1)		
o ICU	7 (8.9)	10 (31.3)		
- Dead	42 (34.7)	23 (41.8)		
o After ICU	11 (26.2)	11 (47.8)	0.103	
Median hospital stay, days	15.5 (7-29)	20 (13-31)	0.098	
Adverse clinical outcome* [N (%)]	49 (40.5)	33 (60)	0.022	
<b>Swab negativization, days (95% CI)</b>				
Median time from symptoms,	35 (29-41)	45 (37.5-52.5)	0.023	0
<b>Fasting glucose (mmol/L)</b>				
Median	8.38 (6.55-10.99)	7.97 (7.43-9.19)	0.882	
- Max	11.04 (8.21-14.62)	9.49 (7.93-11.59)	0.109	
- Min	6.1 (4.85-8.1)	7.04 (5.38-7.71)	0.238	0
- Glucose variability (SD)	2.44 (1.3-3.64)	1.78 (1.01-3)	0.158	
- N° of determinations	3 (2-7)	2 (1-7)	0.043	
<b>Laboratory at admission:</b>				
White blood cells (x10 <sup>9</sup> /L)	7.1 (5.4-10.4)	9.7 (6.1-14.3)	0.004	0
- Neutrophil (x10 <sup>9</sup> /L)	5.2 (3.9-8.1)	8.4 (4.85-12.9)	0.003	2
- Lymphocytes (x10 <sup>9</sup> /L)	0.9 (0.6-1.3)	0.9 (0.6-1.35)	0.55	2
- Monocytes (x10 <sup>9</sup> /L)	0.5 (0.3-0.7)	0.5 (0.3-0.7)	0.5	0
- Haemoglobin (g/L)	12.5 (10.75-13.5)	12.9 (11.5-14.6)	0.042	0
- Platelets (x10 <sup>9</sup> /L)	227 (166-298)	228 (160-344)	0.62	0
- Creatinine (µmol/L)	95.5 (74.3-134.8)	93.7 (76.9-137.9)	0.99	0
- Aspartate transaminase (µkat/L)	0.63 (0.42-1.14)	0.95 (0.65-1.39)	0.001	0
- Alanine transaminase (µkat/L)	0.53 (0.3-0.93)	0.78 (0.47-1.24)	0.012	0
- Lactate dehydrogenase (µkat/L)	5.92 (4.42-8.17)	8.04 (5.35-16.63)	0.001	0
- Albumin (g/L)	27.9 (24.48-30.98)	26.5 (22.7-29.7)	0.17	57
- Total bilirubin (µmol/L)	9.23 (5.39-14.87)	11.62 (8.16-18.81)	0.054	5
- Phosphatase alkaline (µkat/L)	1.27 (0.97-1.92)	1.26 (0.95-1.81)	0.65	29
- Pro-BNP (ng/L)	529 (288-1663)	682 (182-2429)	0.72	64
- Troponin T (µg/L)	19 (11.42-45.57)	26.6 (11.02-88.67)	0.29	44
- D-dimer (µg/ml)	1.69 (0.68-3.83)	2.88 (1.04-6.62)	0.18	39
- PT-INR	1.12 (1.04-1.2350)	1.19 (1.06-1.29)	0.11	15
- PTT-R	1 (0.92-1.1)	0.98 (0.91-1.01)	0.83	15
- Fibrinogen (g/L)	607 (483-746)	570 (433-741)	0.70	85
- Antithrombin III (%)	91 (83.7-100.2)	89.5 (76.2-110)	-	142
- Procalcitonin (ng/ml)	0.61 (0.31-1.38)	0.95 (0.49-3.58)	0.014	42
- Ferritin (µg/L)	823 (462-1499)	1254 (585-2433)	0.063	40
- C reactive protein (mg/L)	93.5 (28.35-172.25)	113.6 (31.1-204.9)	0.39	0
- ESR (mm/h)	73 (39-106)	68 (48-87)	-	98
- IL-6 (pg/ml)	56.4 (23.1-173)	59.8 (27.12-163.25)	0.96	74
<b>Humoral immune response [N (%)]</b>				
Sampling time from symptoms, days	9 (4.75-13)	10 (7-17.75)	0.20	
Anti-GAD antibody	3 (3)	0 (0)	0.55	
- Interferon alpha-4 Antibody	4 (4)	4 (8.3)	0.27	
- SARS-Cov2 RBD IgG	53 (52.5)	27 (56.3)	0.73	
- SARS-Cov2 RBD IgM	56 (55.4)	29 (60.4)	0.60	
- SARS-Cov2 RBD IgA	57 (56.4)	34 (70.8)	0.11	27
- SARS-Cov2 S1+S2 IgG	60 (59.4)	31 (64.6)	0.59	
- SARS-Cov2 S1+S2 IgM	79 (78.2)	35 (72.9)	0.54	
- SARS-Cov2 S1+S2 IgA	76 (75.2)	42 (87.5)	0.13	
- SARS-Cov2 NP IgG	66 (65.3)	35 (72.9)	0.45	

523

\* p-values was not reported for variables that had >50% of missing data



Number at risk

Preexisting	121	51	42	16
New-onset	55	20	14	4





Figure 1

A



Number at risk

Preexisting	121	101	81	61
New-onset	55	35	15	4

B




Figure 2